Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors

by Ruben A. G. van Eerden, Esther Oomen-de Hoop, Aad Noordam, Ron H. J. Mathijssen, Stijn L. W. Koolen
Published 2021-02-01

Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation

by C. Louwrens Braal, Robert J. deKnegt, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen, Karel Eechoute
Published 2022-09-01

Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

by Tessa A. M. Mulder, Mirjam de With, Marzia del Re, Romano Danesi, Ron H. J. Mathijssen, Ron H. N. van Schaik
Published 2021-02-01

Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study

by Daan C. H. van Dorst, Sumeyye Kabadayi, Esther Oomen‐de Hoop, A.H. Jan Danser, Ron H. J. Mathijssen, Jorie Versmissen
Published 2023-01-01

Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen

by Lena Klopp-Schulze, Anna Mueller-Schoell, Anna Mueller-Schoell, Patrick Neven, Stijn L. W. Koolen, Ron H. J. Mathijssen, Markus Joerger, Charlotte Kloft
Published 2020-03-01

Clinically relevant drug interactions with multikinase inhibitors: a review

by Koen G. A. M. Hussaarts, G. D. Marijn Veerman, Frank G. A. Jansman, Teun van Gelder, Ron H. J. Mathijssen, Roelof W. F. van Leeuwen
Published 2019-01-01

Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children.

by Laurens F M Verscheijden, Carlijn H C Litjens, Jan B Koenderink, Ron H J Mathijssen, Marcel M Verbeek, Saskia N de Wildt, Frans G M Russel
Published 2021-03-01

Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report

by Ron H J Mathijssen, Reno Debets, Arjen Joosse, Astrid A M van der Veldt, Marco W J Schreurs, Sharon Veenbergen, Karlijn de Joode, Claudia Kransse, Dian Kortleve
Published 2023-02-01

Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the Netherlands

by Anne Kleijburg, C. Louwrens Braal, Justin D. Westenberg, Agnes Jager, Stijn L.W. Koolen, Ron H.J. Mathijssen, Carin A. Uyl-de Groot, Pim Wetzelaer, Hannah Penton
Published 2023-02-01

Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients

by Daan A.C. Lanser, Maud B.A. Van der Kleij, G.D. Marijn Veerman, Neeltje Steeghs, Alwin D.R. Huitema, Ron H.J. Mathijssen, Esther Oomen-de Hoop
Published 2023-07-01

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients.

by Gaia Schiavon, Alessandro Ruggiero, Patrick Schöffski, Bronno van der Holt, Dave J. Bekers, Karel Eechoute, Vincent Vandecaveye, Gabriel P. Krestin, Jaap Verweij, Stefan Sleijfer, Ron H. J. Mathijssen
Published 2013-01-01

Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis

by Deirdre M.H.J. ten Berge, Daniel P. Hurkmans, Ilse den Besten, Jeroen S. Kloover, Ron H.J. Mathijssen, Reno Debets, Egbert F. Smit, Joachim G.J.V. Aerts
Published 2019-12-01

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple <i>DPYD</i> Variants

by Carin A. T. C. Lunenburg, Linda M. Henricks, André B. P. van Kuilenburg, Ron H. J. Mathijssen, Jan H. M. Schellens, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J. Swen
Published 2018-11-01

Tumor volume as an alternative response measurement for imatinib treated GIST patients.

by Gaia Schiavon, Alessandro Ruggiero, Patrick Schöffski, Bronno van der Holt, Dave J Bekers, Karel Eechoute, Vincent Vandecaveye, Gabriel P Krestin, Jaap Verweij, Stefan Sleijfer, Ron H J Mathijssen
Published 2012-01-01

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients

by Femke M. de Man, Ruben A.G. van Eerden, Esther Oomen-de Hoop, Joris N. Veraart, Nadia van Doorn, Leni van Doorn, Ate van der Gaast, Ron H.J. Mathijssen
Published 2019-06-01

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma

by Koen G. A. M. Hussaarts, Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W. F. van Leeuwen, Stijn L. W. Koolen, Teun van Gelder, Ron H. J. Mathijssen
Published 2021-01-01

The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients

by Leni van Doorn, Marie-Rose B. S. Crombag, Hánah N. Rier, Jeroen L. A. van Vugt, Charlotte van Kesteren, Sander Bins, Ron H. J. Mathijssen, Mark-David Levin, Stijn L. W. Koolen
Published 2021-01-01

Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain

by Bram C. Agema, Astrid W. Oosten, Sebastiaan D.T. Sassen, Wim J.R. Rietdijk, Carin C.D. van der Rijt, Birgit C.P. Koch, Ron H.J. Mathijssen, Stijn L.W. Koolen
Published 2021-06-01

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities

by Yang Li, Yan Jin, Hanieh Taheri, Keith T. Schmidt, Alice A. Gibson, Stefan A. J. Buck, Eric D. Eisenmann, Ron H. J. Mathijssen, William D. Figg, Sharyn D. Baker, Alex Sparreboom, Shuiying Hu
Published 2022-09-01

Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale

by Bram C. Agema, Sanne M. Buijs, Sebastiaan D.T. Sassen, Thomas E. Mürdter, Mathias Schwab, Birgit C.P. Koch, Agnes Jager, Ron H.N. van Schaik, Ron H.J. Mathijssen, Stijn L.W. Koolen
Published 2023-04-01